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It has been demonstrated in previous studies that tin (Sn'+)-protoporphyrin
(SnPP), a potent competitive inhibitor in vitro of the activity of heme oxygenase
(1, 2), the rate-limiting enzyme in the degradation ofheme to bile pigments (3),
blocks the in vivo production of bilirubin and suppresses hyperbilirubinemia in
neonatal rats (4-7), mice with severe genetically determined hemolytic anemia
(8), newborn primates exhibiting physiologic hyperbilirubinemia (9), normal
volunteers (10), patients with elevated levels of plasma bilirubin due to hepatic
dysfunction (11), and term infants with direct Coombs-positive ABO incompati-
bility (12) . The mechanism of action of SnPP has been unequivocally shown to
involve an inhibition of the in vivo catabolism ofheme to bilirubin (4-7) .
Jaundice is common in human newborn and a significant number of infants
require clinical intervention for this condition because bilirubin is potentially a
neurotoxin . At present, effective clinical management of neonatal hyperbiliru-
binemia is limited to phototherapy and to exchange transfusion (13) ; both
treatment modalities are associated with possible side effects, and in the case of
exchange transfusion, mortality . Furthermore, these therapies are designed to
removepreformed bilirubin at a timewhen blood levels of this toxic bile pigment
are either already at high levels or increasing rapidly in newborn infants ; and
the means for applying these treatments are, in any case, often not available to
many babies in third-world countries .
An alternate method of treatment, which is designed to diminish the produc-
tion of bilirubin rather than to dispose of the bile pigment after its formation
and tissue distribution, has been proposed using the heme oxygenase inhibitor
SnPP (1, 2) . SnPP, because of its ability to bind more avidly to the heme-binding
site of heme oxygenase than heme itself (1, 2), inhibits heme degradation and
the production of bilirubin, and thereby suppresses hyperbilirubinemia, thus
offering a new and potentially useful therapy for the clinical management of
hyperbilirubinemia in the newborn .
To further examine the actions of SnPP on naturally occurring forms of
hyperbilirubinemia, we have examined the effect of the compound in the
congenitally jaundiced newborn Gunn rat, an animal model of severe hyperbili-
rubinemia in which UDP-glucuronyl transferase activity for bilirubin is, for
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genetic reasons, absent. This enzyme deficiency mimics the transient deficiency
in bilirubin-conjugating ability that characterizes the newborn and the genetically
determined deficiency of bilirubin glucuronide conjugation from which patients
with the Crigler-Najjar syndrome suffer. The results of this study indicate that
SnPP when administered shortly after birth can block the rapid rise in serum
bilirubin levels that characterizes the Gunn rat in the postnatal period. These
data provide the first demonstration that the severe jaundice that develops in
animals completely deficient in UDP-glucuronyl transferase activity for bilirubin
can be ameliorated by a synthetic heme analogue acting as a competitive inhibitor
of heme oxygenase activity.
Materials and Methods
Rats.
￿
37 newborn homozygous Gunn rats were injected subcutaneously with 50 gmol/
kg body weight SnPP at 24-30 h old immediately after blood was drawn for serum
bilirubin determinations. Of the 37 newborn rats, 14 were reinjected at 6 d old with an
additional 50 umol/kg body weight SnPP and their serum bilirubin concentrations
determined again at 12 d old. 28 untreated newborn homozygous Gunn rats served as
controls; in these neonates serum bilirubin concentrations were determined at 24-30 h
old, at 6 d, and again (n = 23) at 12 d old. All newborn rats were raised with their dams
in an environmentally controlled vivarium so that nutrition and nurturing were not
interrupted. Serum bilirubin concentrations were determined by an AO Bilirubinometer.
In the bile duct-cannulated animal studies, one control and one SnPP-treated animal
were studied at the same time, as previously described (4). SnPP was administered
intravenously through a jugular vein cannula at a dose of 10 A.mol/kg body weight.
Control animals were administered an equivalent volume of saline.
Tissue Preparation.
￿
Livers were perfused in situ with ice-cold 0.9% NaCl and homog-
enized in 3 vol of 0.1 M potassium phosphate buffer, pH 7.4, containing0.25 M sucrose,
and the microsomal fractions were prepared as previously described (1) for the determi-
nation of heme oxygenase activity and cytochrome P450 content. Spleen and kidney
microsomes were prepared in an identical manner. The cytosolic fraction obtained from
the liver of control animals served as a source of biliverdin reductase.
Assays.
￿
The activity of heme oxygenase in all tissues was determined as previously
described (1). Bilirubin formation was calculated using an absorption coefficient of 40
mM-'cm- ' between 464 and 530 mn. Cytochrome P450 was measured by the method of
Omura and Sato using an absorption coefficient of 91 mM-'cm-' between 450 and 490
nm (14) . Bile bilirubin content was measured by the fluorometric method of Roth (15)
and protein content was determined by the method of Lowry et al. (16) using crystalline
BSA as standard. The data were analyzed by Student's t test.
SnPP was purchased from Porphyrin Products, Logan, UT. All other chemicals were
of the highest grade available from either Sigma Chemical Co., St. Louis, MO, or Fisher
Scientific Co., Pittsburgh, PA .
Results
The mean serum bilirubin concentrations of the 28 control newborn rats at
24-30 h old was 6.87 ± 0 .5 mg/dl, and at 6 d old the mean value had increased
to 8.06 ± 0.6 mg/dl (Fig. 1). The mean serum bilirubin concentration of the 37
pups that were injected with SnPP 24-30 h after birth was 6.56 ± 0.4 mg/dl, a
value comparable to the controls; at 6 d old, SnPP-treated pups had a mean
serum bilirubin of 6 .54 ± 0.4 mg/dl, unchanged from that at birth, whereas the
serum bilirubin levels in the control pups, as noted, underwent the normal
postnatal increase in bilirubin observed in these animals. The difference in mean
values was statistically significant (p <0.05) at 6 d postpartum.12
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TABLE I
Bilirubin
Mean t SE, n = 7. Bilirubin measured 6 h before and 15 h after SnPP was administered
intravenously at 10 umol/kgbody weight.
* p <0.01 compared to control period.
The serum bilirubin concentrations of the 23 controls were again measured
at 12 d old. The serum concentration of the bile pigment, as expected, had
continued to rise to a mean value ± SE of 10.98 ± 0.6 mg/dl (Fig. 1). The serum
bilirubin levels of the 14 pups injected with SnPP at 24-30 h old, and reinjected
at 6 d old were also determined at 12 d. In contrast to the controls, the mean
serum bilirubin level ± SE of the treated neonates was 6.85 ± 0.6 mg/dl (Fig.
1) . Thus, the SnPP-treated animals maintained a constant serum bilirubin con-
centration after two treatments with SnPP postpartum, whereas the serum
bilirubin levels in control animals underwent the rapid, substantial increase
characteristic ofthese UDP-glucuronyl transferase-deficient animals. The values
at 12 d were significantly lower for the SnPP-treated pups compared with controls
(p <0.001).
The output of bilirubin in bile in seven bile duct-cannulated rats treated with
SnPP, 10 Amol/kg body weight, compared with seven similar controls treated
with saline, is shown in Table I. This dose of SnPP was the lowest effective dose
of the metalloporphyrin that was shown in previous studies to diminish biliary
bilirubin output in normal bile duct-cannulated rats (4). SnPP administration
resulted in a statistically significant (p <0 .01) decrease in the output of bilirubin
in the bile of SnPP-treated Gunn rats as compared with the decline in biliary
bilirubin output usually observed in the postsurgical period in control animals.
The average net decrease in bilirubin output produced by SnPP was 31 .8%
compared with 19.5% for the untreated animals. The activity of heme oxygenase
in liver, kidney, and spleen of SnPP-treated bile duct-cannulated animals was
significantly lower than identically treated control animals administered saline
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Before After
'+g/min Ng/min
Saline 0.87 t 0.05 0.70 f 0.02 -19.5
SnPP 1.07 t 0.05 0.73±0.01* -31.81250
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TABLE II
Effect ofSnPP on Tissue Heme OxygenaseActivity in the Bile Duct-cannulated Gunn Rat
Tissue
Heme oxygenase
(nmolbilirubin/mg per h) Change
Mean t SE, n = 7; SnPP was administered intravenously at 10 umol/kgbody weight.
*p <0.001 when compared with control.
$p <0.01 when compared with control.
(Table II). In addition, the levels of hepatic cytochrome P450 remained un-
changedin thebileduct-cannulated Gunnrat afterSnPPadministration (control,
0.59 ± 0.04 nmol/mg; SnPP 0.64 ± 0.03 nmol/mg; mean ± SE, n = 7).
Discussion
The results of the experiments described above provide confirmation of our
previous studies showing that SnPP inhibits the in vivo catabolism of heme and
suppresses hyperbilirubinemia in a wide variety of experimentally induced and
naturally occurring forms ofjaundice in animals and man, including newborn
infants (12). In this study, however, theinhibition was demonstrated in the Gunn
rat, an animal completely deficient in the enzyme activity, UDP-glucuronyl
transferase for bilirubin, and thus in the ability to conjugate and excrete this bile
pigment in normal fashion. The resulting severe hyperbilirubinemia is a patho-
logic condition, permanent rather than transient, but which mimics in certain
respects thejaundice that develops in human neonates, who at birth are charac-
terized by a cholestatic state, have a transient deficiency in UDP-glucuronyl
transferaseactivity, and thus display an impaired abilityto conjugate and excrete
bilirubin atnormal rates. This developmentally dependentdeficiency inbilirubin-
conjugating ability coupled with the excessive rate at which heme is catabolized
postnatally to bile pigments accounts in large part for the severe hyperbilirubi-
nemia that develops in many newborn infants.
As these studies show, in the naturally occurring, genetically determined form
of severe neonataljaundice in the Gunn rat, SnPP acts effectively to prevent the
marked increase in serum bilirubin concentration that occurs in the immediate
postnatal period, in the same manner as it does in normal neonatal animals and
in adult animals treated with exogenous heme (4). Moreover, a repeat injection
of SnPP at 6 d old maintained the inhibition of bilirubin production and
prevented the rapid increase in blood levels of this bile pigment that would
otherwise be anticipated during the initial 12 d of the postnatal period in the
Gunn neonates. On the basis of earlier work in mice, severely jaundiced as a
result of genetically determined hemolytic anemias, the SnPP effect would be
expected to be sustained as long as the inhibitor was being administered (8). It
is possible that SnPP would not control serum bilirubin levels in mature Gunn
rats as effectively as it does in neonates, since early administration of the
Saline SnPP
Liver 3.97 f 0.38 1.08 t 0.23* -73
Kidney 1.34 t 0.31 0.72 t 0.15 -46
Spleen 10.44 ± 1.26 4.77 ± 0.42$ -54SISSON ET AL .
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compound in the newborn would be expected to diminish the accumulation of
bilirubin in tissue sites, which characterizes the adult Gunn rat .
The administration of the metalloporphyrin resulted in a significant decrease
in bilirubin output in bile (Table 1) in the adult homozygous Gunn rat, an action
similar to that of the compound in normal experimental animals (4, 7) and in
normal humanvolunteers (10) . This decrease in biliary bilirubin output occurred
without an increase in plasma bilirubin levels, clearly indicating that SnPP
behaves in the Gunn rat in a manner similar to that observed in animals with
normal bilirubin-conjugating ability (4, 7) . Since essentially all bilirubin formed
from heme catabolism undergoes biliary excretion, based on these experiments
and the extensive data presented in other reports (4, 7), the decreased output of
biliary bilirubin is most reasonably explained by an SnPP inhibition ofproduction
of the bile pigment. The substantial diminution in the activities of hepatic,
splenic, and renal heme oxygenase in the SnPP-treated Gunn rats support this
view (Table II).
It is interesting to note that SnPP administration had no effect on the levels
of cytochrome P450 in the bile duct-cannulated Gunn rat. The dose of SnPP
administered (10 jumol/kg body weight) was substantially (15-20-fold) greater
than that used to significantly diminish the increases in plasma bilirubin that
occur in the immediate postnatal period in term infants with direct Coombs
positive ABO incompatibility (12) . Thus, within the range of the small doses of
SnPP that might conceivably be used clinically, based on the studies described
above, no significant influence of the compound on cytochrome P450 content
or function would be expected to occur.
The demonstration that even in the Gunnrat-an animal species characterized
by a genetically determined absence of UDP-glucuronyl transferase activity for
bilirubin-SnPP administration can substantially block the marked increases in
plasma bilirubin levels that occur in the immediate postnatal period affirms the
potency of this enzyme inhibitor to block bilirubin production in vivo . These
findings also raise the possibility that SnPP, or a related heme oxygenase inhibitor
(17), might prove useful in maintaining low plasma levels of bilirubin in patients
with the Crigler-Najjar syndrome, a genetic disorder in which there is a partial
deficiency of UDP-glucuronyl transferase, and in whichpatients areat substantial
risk of neurotoxicity due to the sustained severe hyperbilirubinemia associated
with this syndrome .
Summary
Administration of Sn-protoporphyrin to Gunn rats that are characterized by a
genetically determined absence of UDP-glucuronyl transferase activity for bili-
rubin, 24-30 h after birth, prevented the marked increase in serum bilirubin
concentration that occurs in these animals in the postnatal period . A second
administration of Sn-protoporphyrin at day 6 maintained serum bilirubin levels
in the neonates at the initial level for an additional 6d. In contrast, in untreated
Gunn neonates, serum bilirubin levels increased substantially as expected during
the immediate 2-wk period after birth. Studies in adult Gunn rats demonstrated
that Sn-protoporphyrin administration diminished biliary bilirubin output, de-
creased tissue heme oxygenase activity, and did not alter hepatic cytochrome
P450 levels . These findings raise the possibility that Sn-protoporphyrin may1252
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prove clinically useful in maintaining low levels of serum bilirubin in congenitally
jaundiced individuals, such as patients with the Crigler-Najjar syndrome.
Receivedfor publication 2 December 1987.
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